The company said, “The Company is well funded with a strong cash and cash equivalent, and term deposit balance as at 30 September 2025 of approximately A$109.85M, which is in line with budget as at the beginning of FY2026, while progressing our clinical programs within announced timeframes. The total balance consists of: a cash and cash equivalent balance of A$83.41M and bank term deposits totaling A$26.44M, which have been recognised as short-term investments due to having maturities of more than 3 months and less than 12 months.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP:
- Immutep Showcases Promising Lung Cancer Treatment Results at ESMO Congress 2025
- Immutep Announces Breakthrough Results in Soft Tissue Sarcoma Trial
- Immutep presents two posters at ESMO on changing landscape for 1L NSCLC
- Immutep announces Phase II study of eftilagimod alfa met primary endpoint
- Immutep Completes FDA Project Optimus, Advances Efti Trials